Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 6/20 | 1.00 |
| ▸ | CA2 | P00918 | 6/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 12/20 | 0.69 |
| ▸ | PDE4A | P27815 | 10/20 | 0.69 |
| ▸ | PDE4C | Q08493 | 10/20 | 0.69 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.69 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | PDE1A | P54750 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.48 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tavaborole SCHEMBL500016 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL19171231 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| Tavaborole SCHEMBL29372574 | 1.00 | CA1 (1.00) | CA1CA2PDE3APDE4BPDE4A | |
| Tavaborole SCHEMBL28132066 | 0.89 | CA1 (0.79) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL19171283 | 0.85 | CA1 (0.72) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL5583464 | 0.85 | CA1 (0.73) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL499993 | 0.85 | CA1 (0.73) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL500220 | 0.83 | CA1 (0.71) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL5583179 | 0.83 | CA1 (0.71) | CA1CA2PDE3APDE4BPDE4A | |
| SCHEMBL2532096 | 0.82 | PDE4B (1.00) | CA1CA2PDE3APDE4BPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10457695-B2 | Process for the preparation of tavaborole | GLENMARK LIFE SCIENCES LIMITED (IN) | 2019-10-29 | — | — | US | disclosed |
| US-20190023724-A1 | PROCESS FOR THE PREPARATION OF TAVABOROLE | ALIVUS LIFE SCIENCES LIMITED (IN) | 2019-01-24 | — | — | US | disclosed |
| US-8115026-B2 | Boron-containing small molecules | ANACOR PHARMACEUTICALS, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20070155699-A1 | Boron-containing small molecules | ANACOR PHARMACEUTICALS (US) | 2007-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190023724-A1 | PROCESS FOR THE PREPARATION OF TAVABOROLE | VPS4B, SQLE, F5 | CA1 3525/4885CA2 3642/4885PDE3A 2320/4885 |
| US-10457695-B2 | Process for the preparation of tavaborole | VPS4B, SQLE, F5 | CA1 3525/4885CA2 3642/4885PDE3A 2320/4885 |
| US-20070155699-A1 | Boron-containing small molecules | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885PDE3A 4505/4885 |
| US-20100267981-A1 | BORON-CONTAINING SMALL MOLECULES | ETF1, POLR1C, DPM1 | CA1 4091/4885CA2 1368/4885PDE3A 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.